Isolation and biological activity of triglycerides of the fermented mushroom of Coprinus Comatus
© Ren et al; licensee BioMed Central Ltd. 2012
Received: 5 September 2011
Accepted: 24 April 2012
Published: 24 April 2012
Although many physiological functions of Coprinus comatus have been reported, there has been no report on the antinociceptive activity of Coprinus comatus. Therefore, the objective of the present study is to demonstrate the production, isolation, and biological properties of triglycerides (TFC) of the fermented mushroom of Coprinus comatus.
The effects of TFC on cytokines levels, total antioxidant activity, antinociceptive effects in vivo, LD50 and tactile hyperalgesia were analyzed respectively.
TFC treatment decreased the levels of cytokines and total antioxidant status (TAOS) and inhibited the acetic acid-induced abdominal constrictions in mice. In addition, TFC reduced CFA-induced tactile hyperalgesia in a dose-dependent manner and the LD50 of TFC was determined to be 400 mg/kg. However, TFC did not significantly inhibit the reaction time to thermal stimuli in the hot-plate test.
TFC showed anti-inflammatory, antioxidant, peripheral antinociceptive and antihyperalgesic activity in various models of inflammatory pain. The data suggest that TFC may be a viable treatment option for inflammatory pain.
Edible fungi have a long history of use in Traditional Chinese Medicine . Coprinus comatus is a basidiomycete fungus claimed to benefit glycaemic control in diabetes. Many physiological functions of Coprinus comatus have been reported, such as anti-cancer properties , immunomodulatory  and hypoglycemic activity . Stadler et al. reported that agaricoglycerides, a new class of fungal secondary metabolites isolated from several basidiomycetes, showed strong activities against neurolysin, a protease involved in the regulation of dynorphin and neurotensin metabolism, and even exhibited moderate analgesic in vivo. The agaricoglycerides are a new class of fungal secondary metabolites that constitute esters of chlorinated 4-hydroxy benzoic acid and glycerol. Although the crude extract from Coprinus comatus was no beneficial effect at lower doses in mice subjected to acetic-acid writhing test, formalin test and hot-plate test , there has been no report on the antinociceptive activity of agaricoglycerides extract from Coprinus comatus. Therefore, the objectives of the present study were to demonstrate the production, isolation, and biological properties of triglycerides of the fermented mushroom of Coprinus comatus.
Fermented mushroom of Coprinus comatus
The seed of Coprinus comatus was purchased from the Agricultural Culture Collection of China.
First, the seed was grown at 28°C for 5 days on PDA slants (1,000 mL 20% potato extract liquid +20.0 g dextrose +20.0 g agar) and then maintained at 4°C in a refrigerator. Five to six pieces of the mycelia of Coprinus comatus were transferred from a slant into 250 mL Erlenmeyer flasks containing 100 mL liquid medium (20% potato extract liquid +2.0% dextrose +0.1% KH2PO4 + 0.05% MgSO2). The culture was incubated at 27°C on a rotary shaker at 180 rpm for 5 days.
A 120-h-old liquid culture was homogenized using a sterilized blender and then inoculated to 500 mL Erlenmeyer flasks containing 300 mL of fermented culture medium. The volume of inoculum was 15 mL, which was then cultivated under the same condition. The 168-h-old culture medium was used for extraction [7–9].
Triglycerides extracted from fermented mushroom of Coprinus comatus (TFC)
The methodology for extraction of triglycerides was described in detail by Han et al. . Briefly, mycelia were separated from the culture fluid by filtration and extracted twice with acetone in an ultrasonic bath. The extract was filtered, and the acetone was removed in vacuo to yield an aqueous residue. This residue was diluted with tap water and subsequently extracted three times with EtOAc. The combined organic phases were dried over Na2SO4 and evaporated in vacuo to yield an oily residue.
Acute toxicity study
When there is no information of TFC on toxicity, it is recommended to use the starting dose of 250 mg/kg body weight. The animals were given intraperitoneally the lowest with dose of 250 mg/kg of the compounds at the first instance. If more than 50% mice die within 24 hrs, another group was chosen at a dose of 200 mg/kg. If no death was observed, increasing dose up to limit dose of 2,000 mg/kg was injected to the mice. If more than 50% death was observed in limit test, the dose was then reduced to 800 mg/kg. Acute half lethal dose (LD50) was determined after observing toxic reaction for three days.
Anti-inflammatory effect of TFC on cytokines levels
Wistar rats (weighing 225 ± 25 g) were used in the study. This study was performed in accordance with the Guide for the Care and Use of Laboratory Animals. The study was approved by the ethics committee of Chinese Academy of Sciences, and all procedures complied with the guidance set out in the Guidelines for Caring for Experimental Animals published by the Ministry of Science and Technology of the People's Republic of China. Care was taken to minimize discomfort, distress, and pain to the animals. Forty healthy female adult rats were randomly divided in four groups. The TFC were presolubilized in mixture of DMSO, ethanol and polysorbate-80. This mixture was subsequently filled up with physiological saline to final concentrations of 4% DMSO, 10% ethanol and 20% polysorbate-80. Intraperitoneal doses of 10, 20 and 30 mg/kg body weight were applied in a volume of 2 ml/kg 1 h before the injection of carrageenan. Diclofenac sodium (1.7 mg/kg) was used as a standard. Inflammatory response was induced by a single intrapleural injection of 0.1 mLof sterile saline solution (NaCl, 0.95%) plus carrageenan (Cg, 1%). Ten healthy rats treated only with intrapleural injection (i.p.) of sterile saline solution (NaCl 0.95%) used as control group. Six hours after the injection of carrageenan, blood samples were drawn from orbital vein from all the groups and serum was separated for biochemical estimations.
The level of TNF-α, IL-1β, VEGF-α, and IL-17 in the rat blood samples were measured as previously described by Cai et al. . Briefly, protein was extracted from the blood samples and the concentration was adjusted to 4 mg/ml. The concentration of TNF-α, IL-1β, VEGF-α, and IL-17 were then determined using a commercial ELISA kit (Shanghai Jinma Biological Technology, Inc., China) following the manufacture’s instruction.
Measurement of total antioxidant status
The total antioxidant status (TAOS) of serum was determined as previously described by Laight et al. . The increase of absorbance at 405 nm was measured by a microplate reader (Shanghai Xunda Medical Technology, Inc., China).
Peripheral antinociceptive effect of TFC in animal model
Kunming outbred mice weighing 20-22 g, were purchased from the Experimental Animal Center, Shandong University. The mice were maintained at room temperature under alternating natural light/dark photoperiod, and had access to standard laboratory food and fresh water ad libitum.
Writhing test is used for the evaluation of peripheral analgesic activity. Mice were treated (intraperitoneal) with TFC of 10, 20 and 30 mg/kg body weight 60 min before receiving a 0.6% acetic acid injection (10 mL/kg, i.p.). The number of contractions or writhings, determined by abdominal muscle contractions and hind paw extension was recorded for 20 min, starting 10 min after the administration of acetic acid. Diclofenac sodium (1.7 mg/kg) was used as standard.
Central antinociceptive effect of TFC in animal model
The hot-plate test is commonly used to assess narcotic analgesics or other centrally acting drugs [13, 14]. In this test, mice were pre-selected according to their reactions to a thermal stimulus (jumping or licking of hind limbs when placed on a hot plate at 55°C). Latency times were recorded immediately before and 30, 60 and 90 min after drug administration (intrapleural injection with TFC of 10, 20and 30 mg/kg body weight, diclofanac sodium 1.7 mg/kg and sterile saline), up to a maximum time of 40 s to avoid paw lesions .
Anti-hyperalgesia effect of TFC in animal model
Mice received a single intraplantar injection of 100 μl of 1 mg/ml dose of heat-killed and dried Mycobacterium tuberculosis in a mixture of paraffin oil and mannide monoleate. The tactile hyperalgesia was tested as tactile withdrawal threshold before and at 15, 30 and 60 min after drug administration.
The data were expressed as mean ± S.E.M. and results were analyzed by ANOVA followed by Dunnett’s t test. P < 0.05 was considered significant.
Results and discussion
The present study demonstrates, for the first time, that the anti-inflammatory and analgesic effects of TFC. Carrageenan-induced inflammation in rats is a well-characterized experimental model of acute inflammation that permits the quantification and correlation of cellular migration with changes in other inflammatory parameters . Diclofenac is a nonsteroidal anti-inflammatory drug used to treat pain andinflammation associated with arthritis. It was used as a standard. The inflammatory response involves a complex intercellular signal promoting cytokine release. Activated inflammatory cells synthesize and secrete proinflammatory cytokines such as TNF-α, IL-1β, VEGF-α, and IL-17 [17–19]. The suppression of these proinflammatory mediators has been found to reduce the severity of the inflammatory reaction . Some work has been done on the effects of the mushroom on cytokines and nuclear factor kappa B (NF-κB) levels [21–25]. The present study was undertaken to determine the effect of TFC on protein levels of TNF-α, IL-1β, VEGF-α, and IL-17 during the inflammatory process induced by carrageenan.
Effect of TFC on the Protein Levels of TNF-α, IL-1β, VEGF-α, and IL-17
3021.0 ± 388.4
1066.6 ± 148.8
1212.2 ± 117.7
867.1 ± 58.4
1620.6 ± 118.0**
676.7 ± 64.0 **
675.5 ± 22.5 **
91.5 ± 6.5***
TFC 10 group
2718.7 ± 370.2
1084.0 ± 84.3
1090.0 ± 44.1
771.7 ± 75.7
TFC 20 group
2013.4 ± 184.7
866.7 ± 70.3
1054.4 ± 44.5
671.1 ± 35.5
TFC 30 group
1260.4 ± 195.5**
777.7 ± 66.3 *
648.0 ± 20.2 **
93.5 ± 9.5***
Peripheral antinociceptive effect of TFC in mice subjected to the writhing test
Number of contraction (20 min)
25.1 ± 2.2
5.8 ± 1.9
TFC 10 group
15.0 ± 2.1*
TFC 20 group
7.6 ± 1.6**
TFC 30 group
5.8 ± 1.2**
Effect of TFC in mice subjected to the hot-plate test. (N = 10)
Reaction time to the thermal stimulus (s)
10.9 ± 0.6
9.6 ± 0.9
8.3 ± 0.80
9.5 ± 0.6
9.9 ± 0.8
13.0 ± 1.1*
16.3 ± 0.6**
16.8 ± 1.5**
TFC 10 group
11.9 ± 1.5
11.4 ± 1.5
8.8 ± 1.2
11.4 ± 1.3
TFC 20 group
10.9 ± 2.2
11.5 ± 1.2
9.8 ± 1.1
10.6 ± 1.3
TFC 30 group
13.9 ± 1.1
11.2 ± 0.9
11.4 ± 1.7
12.5 ± 2.9
As per the OECD Guidelines-423, LD50 was calculated for TFC. When there is no information of TFC on toxicity, it is recommended to use the starting dose of 250 mg/kg body weight. This involves the estimation of the median lethal dose (LD50), which is the dose that will kill 50% of the animal population within 72 hours post treatment with the test substance. After intraperitoneal injection, most mice in the 400 mg/kg group were quiet and inactive. Mice died approximately 7 hr after injection. The majority of mice in the 400 mg/kg dose group (5 mice) died within 72 hr following the injection. The LD50 was determined to be 400 mg/kg.
In conclusion, TFC showed anti-inflammatory, antioxidant, peripheral antinociceptive and antihyperalgesic activity in various models of inflammatory pain. The data suggest that TFC may be a viable treatment option for inflammatory pain.
This project was supported by the Key New Drugs Innovation project from Ministry of Science and Technology (2009ZX09103-381, 2009ZX09502-017, 2010ZX09102-201-018), the project from Key Laboratory of Mental Health, Chinese Academy of Sciences, project of Shandong Province Higher Educational Science and Technology Program (J08LH62), NNSF grant (30800301, 31170992) and the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-254, KSCX2-EW-Q-18 and KSCX2-EW-J-8).
- Demirbas A: Heavy metal bioaccumulation by mushrooms from artificially fortified soils. Food Chem. 2001, 74: 293-301. 10.1016/S0308-8146(01)00155-8.View Article
- Cui M, Zhang H, An L: Tumor growth Inhibition by polysaccharide from Coprinus comatus. World Chin J Digestol. 2002, 10: 287-290.
- Xing F, Wang H, Han C, Wang Y: Study on the immunocompetence of polysaccharides from the Coprinus comatus. J Food Sci (In Chinese). 2003, 24: 139-141.
- Gu Y, Ju Y: Food and officinal mushroom-Coprinus comatus. Vegetable (In Chinese). 1996, 13: 10-
- Stadler M, Hellwig V, Mayer-Bartschmid A, Denzer D, Wiese B, Burkhardt N: Novel Analgesic Triglycerides from Cultures of Agaricus macrosporus and Other Basidiomycetes as Selective Inhibitors of Neurolysin. J Antibiot (Tokyo). 2005, 58: 775-786. 10.1038/ja.2005.105.View Article
- Han C: A comparison of antinociceptive activity of mycelial extract from three species of fungi of basidiomycetes. Open Complement Med J. 2009, 1: 73-77. 10.2174/1876391X00901010073.View Article
- Lv Y, Han L, Yuan C, Guo J: Comparison of hypoglycemic activity of trace elements absorbed in fermented mushroom of Coprinus comatus. Biol Trace Elem Res. 2009, 131: 177-185. 10.1007/s12011-009-8352-7.View ArticlePubMed
- Xu Q, Guo J: Activity and toxicity of Cr (III)-enriched Grifola frondosa in insulin-resistant mice. Biol Trace Elem Res. 2009, 131: 271-277. 10.1007/s12011-009-8364-3.View ArticlePubMed
- Guo JY, Han CC, Liu YM: A contemporary treatment approach to both diabetes and depression by cordyceps sinensis, rich in Vanadium. Evid Based Complement Alternat Med. 2010, 7: 387-389. 10.1093/ecam/nep201.PubMed CentralView ArticlePubMed
- Han CC: Antinociceptive activity of agaricoglycerides extracted from mycelium of Ling Zhi or Reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst. (Aphyllophoromycetideae). Int J Med Mushrooms. 2010, 12: 273-278. 10.1615/IntJMedMushr.v12.i3.60.View Article
- Cai Z, Pang Y, Lin S, Rhodes PG: Differential roles of tumor necrosis factor-alpha and interleukin-1 beta in lipopolysaccharide-induced brain injury in the neonatal rat. Brain Res. 2003, 975: 37-47. 10.1016/S0006-8993(03)02545-9.View ArticlePubMed
- Laight DW, Gunnarsson PT, Kaw AV, Carrier MJ: Physiological microassay of plasma total antioxidant status in a model of endothelial dysfunction in the rat following experimental oxidant stress in vivo. Environ Toxicol Pharmacol. 1999, 7: 27-31. 10.1016/S1382-6689(98)00046-5.View ArticlePubMed
- Guo JY, Wang JY, Luo F: Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. J Psychopharmacol. 2010, 24: 1561-1567. 10.1177/0269881109104848.View ArticlePubMed
- Guo JY, Yuan XY, Sui F, Zhang WC, Wang JY, Luo F, Luo J: Placebo analgesia affects the behavioral despair tests and hormonal secretions in mice. Psychopharmacology. 2011, 217: 83-90. 10.1007/s00213-011-2259-7.View ArticlePubMed
- Woolfe G, MacDonald AD: The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther. 1944, 80: 300-307.
- Moore AR: Pleural models of inflammation: immune and nonimmune. Methods Mol Biol. 2003, 225: 123-128.PubMed
- Calcagni E, Elenkov I: Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann N Y Acad Sci. 2006, 1069: 62-76. 10.1196/annals.1351.006.View ArticlePubMed
- Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M: Immune response modiiers-mode of action. Exp Dermatol. 2006, 15: 331-341. 10.1111/j.0906-6705.2006.00414.x.View ArticlePubMed
- Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S: The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inlammation. Int Immunol. 2008, 20: 1361-1368. 10.1093/intimm/dxn106.View ArticlePubMed
- Stow JL, Ching Low P, Offenhäuser C, Sangermani D: Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiology. 2009, 214: 601-614. 10.1016/j.imbio.2008.11.005.View ArticlePubMed
- Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ: Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol. 2008, 8: 1124-1133. 10.1016/j.intimp.2008.04.004.View ArticlePubMed
- Asatiani MD, Wasser SP, Nevo E, Ruimi N, Mahajna J, Reznick AZ: The Shaggy Inc Cap medicinal mushroom, Coprinus comatus (O.F.Mull.: Fr.) Pers.(Agaricomycetideae) substances interfere with H2O2 induction of the NF-kappaB pathway through inhibition of Ikappaalpha phosphorylation in MCF7 breast cancer cells. Int J Med Mushrooms. 2011, 13: 19-25. 10.1615/IntJMedMushr.v13.i1.30.View ArticlePubMed
- Beattie KD, Ulrich R, Grice ID, Uddin SJ, Blake TB, Wood KA, Steele J, Iu F, May TW, Tiralongo E: Ethanolic and aqueous extracts derived from Australian fungi inhibit cancer cell growth in vitro. Mycologia. 2011, 103: 458-465. 10.3852/10-121.View ArticlePubMed
- Gu YH, Leonard J: In vitro effects on proliferation, apoptosis and colonyinhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. Oncol Rep. 2006, 15: 417-423.PubMed
- Zaidman BZ, Wasser SP, Nevo E, Mahajna J: Coprinus comatus andGanoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Mol Boil Rep. 2008, 35: 107-117. 10.1007/s11033-007-9059-5.View Article
- Vega VL, Maldonado M, Mardones L, Manríquez V, Vivaldi E, Roa J, Ward PH: Inhibition of nitric oxide synthesis aggravates hepatic oxidative stress and enhances superoxide dismutase inactivation in rats subjected to tourniquet shock. Shock. 1998, 9: 320-328. 10.1097/00024382-199805000-00002.View ArticlePubMed
- Li B, Lu F, Suo X, Nan H: Antioxidant properties of cap and stipe fromCoprinus comatus. Molecules. 2010, 15: 1473-1486. 10.3390/molecules15031473.View ArticlePubMed
- Popovic M, Vukmirovic S, Stilinovic N, Capo I, Jakovljevic V: Anti-oxidative activity of an aqueous suspension of commercial preparation of the mushroom Coprinus comatus. Molecules. 2010, 15: 4564-4571. 10.3390/molecules15074564.View ArticlePubMed
- Sabo A, Stilinovic N, Vukmirovic S, Bukumiric Z, Capo I, Jakovljevic V: Pharmacodynamic action of a commercial preparation of the mushroom Coprinus comatus in rats. Phytother Res. 2010, 24: 1532-1537. 10.1002/ptr.3182.View ArticlePubMed
- Collier HOJ, Dinneen JC, Johnson CA, Schneider C: The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Chemother. 1968, 32: 295-310.PubMed CentralView ArticlePubMed
- Deraedt R, Jouquey S, Delevalée F, Flahaut M: Release of prostaglandins-E and prostaglandins-F in an algogenic reaction and its inhibition. Eur J Pharmacol. 1980, 61: 17-24. 10.1016/0014-2999(80)90377-5.View ArticlePubMed
- DiNunzio JC, Williams RO: CNS disorders–current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm. 2008, 34: 1141-1167. 10.1080/03639040802020536.View ArticlePubMed
- Ma QP, Woolf CJ: Progressive tactile hypersensitivity: an inflammation induced incremental increase in the excitability of the spinal cord. Pain. 1996, 67: 97-106. 10.1016/0304-3959(96)03105-3.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/52/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.